The Global Health Body Raises Warning Over Critical Lack of Weight-Loss Jabs
Fewer than one in 10 people who could benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it publishes its initial guidance on the therapies.
With more than one billion individuals worldwide now obese, it is calling for more widespread and fairer access to these injectable treatments.
Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidelines recognises that excess weight is a chronic disease that can be treated with comprehensive and continuous treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major hurdles to broad availability to the injections that can aid individuals in losing considerable body mass, explains the agency.
Weight-Loss Drug Supply Crisis
Despite the current best projected scenario, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of those who need them, per the health organization.
The recommendation urges nations and manufacturers to increase access, by measures including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Obesity Drugs Operate
The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and boost satiety so people reduce food intake.
People commonly see weight reduction in the initial weeks of starting on the once-weekly jabs.
Evidence indicates users may regain a significant portion a year later of halting the treatment, as their usual food cravings return.
Being carrying excess weight increases your risk for experiencing diseases, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects people in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the health agency.
